[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial].Minerva Med. 1996 Apr; 87(4):155-60.MM
Abstract
We tested the therapeutic response of osteoarthrosis subjects to 30 mg piroxicam cinnamate (Sinartrol). The double-blind study was conducted in 2 homogeneous groups of 30 patients each treated with piroxicam cinnamate one 30-mg tablet twice daily for 2 days followed by 1 tablet daily for further 13 days and with piroxicam cinnamate 20 mg tablets (according to the same posologic scheme) respectively. The results obtained demonstrate the efficacy of this new piroxicam cinnamate formulation which led to a significant clinical improvement, already evident after 2 days of treatment and even more evident at the end of therapy. Patients compliance to treatment was good and side effects were scarce and spontaneously subsiding.
MeSH
Pub Type(s)
Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial
Language
ita
PubMed ID
8700339
Citation
Peretti, G. "[Clinical Evaluation of 30 Mg Cinnoxicam in Patients With Osteoarthrosis. Double Blind Controlled Trial]." Minerva Medica, vol. 87, no. 4, 1996, pp. 155-60.
Peretti G. [Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial]. Minerva Med. 1996;87(4):155-60.
Peretti, G. (1996). [Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial]. Minerva Medica, 87(4), 155-60.
Peretti G. [Clinical Evaluation of 30 Mg Cinnoxicam in Patients With Osteoarthrosis. Double Blind Controlled Trial]. Minerva Med. 1996;87(4):155-60. PubMed PMID: 8700339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - [Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial].
A1 - Peretti,G,
PY - 1996/4/1/pubmed
PY - 1996/4/1/medline
PY - 1996/4/1/entrez
SP - 155
EP - 60
JF - Minerva medica
JO - Minerva Med
VL - 87
IS - 4
N2 - We tested the therapeutic response of osteoarthrosis subjects to 30 mg piroxicam cinnamate (Sinartrol). The double-blind study was conducted in 2 homogeneous groups of 30 patients each treated with piroxicam cinnamate one 30-mg tablet twice daily for 2 days followed by 1 tablet daily for further 13 days and with piroxicam cinnamate 20 mg tablets (according to the same posologic scheme) respectively. The results obtained demonstrate the efficacy of this new piroxicam cinnamate formulation which led to a significant clinical improvement, already evident after 2 days of treatment and even more evident at the end of therapy. Patients compliance to treatment was good and side effects were scarce and spontaneously subsiding.
SN - 0026-4806
UR - https://www.unboundmedicine.com/medline/citation/8700339/[Clinical_evaluation_of_30_mg_cinnoxicam_in_patients_with_osteoarthrosis__Double_blind_controlled_trial]_
L2 - https://medlineplus.gov/osteoarthritis.html
DB - PRIME
DP - Unbound Medicine
ER -